Article

microRNA-183 is an oncogene targeting Dkk-3 and SMAD4 in prostate cancer.

Department of Urology, San Francisco Veterans Affairs Medical Center, University of California at San Francisco, 4150 Clement Street, San Francisco, CA 94121, USA.
British Journal of Cancer (Impact Factor: 5.08). 03/2013; DOI: 10.1038/bjc.2013.125
Source: PubMed

ABSTRACT Background:The purpose of this study was to identify prostate cancer (PC) oncogenic microRNAs (miRs) based on miR microarray and to investigate whether these oncogenic miRs may be useful as PC biomarkers.Methods:Initially, we carried out miR microarray and real-time PCR using RWPE-1, PC-3, DU-145 and LNCaP cells. To investigate the function of miR-183, we used a miR-183 knockdown inhibitor in cell growth and wound-healing assays. We used several algorithms and confirmed that they are directly regulated by miR-183.Results:We identified three potential oncogenic miRs (miR-146a, miR-183 and miR-767-5P). The expression of miR-183 in PC cells (PC-3, DU-145 and LNCaP) was upregulated compared with RWPE-1 cells. MiR-183 expression was also significantly higher in PC tissues compared with that in matched normal prostate tissues. Additionally, miR-183 expression was correlated with higher prostate-specific antigen, higher pT and shorter overall survival. MiR-183 knockdown decreased cell growth and motility in PC cells and significantly decreased prostate tumour growth in in vivo nude mice experiments. We identified Dkk-3 and SMAD4 as potential target genes of miR-183.Conclusion:Our data suggest that oncogenic miR-183 may be useful as a new PC biomarker and that inhibition of miR-183 expression may be therapeutically beneficial as a PC treatment.British Journal of Cancer advance online publication, 28 March 2013; doi:10.1038/bjc.2013.125 www.bjcancer.com.

0 Bookmarks
 · 
83 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: The aim of this study was to investigate the function of miR-183 in the SW1990 cancer cell line, and the mechanisms regulating these processes. miRNAs are known to play important roles in cancer cell development. However, the pattern and biological role of miR-183 in pancreatic cancer remain largely unknown. Here, we have reported the reduction in pancreatic cancer cell growth in vitro by miR-183 intervention, by inducing apoptosis and decreasing the Bcl-2 expression. Moreover, miR-183 was observed to enhance pancreatic cancer cell migration and invasion, whereas inhibition of miR-183 caused an opposite effect. miR-183 inhibition was shown to increase E-cadherin expression and decrease N-cadherin expression. These regulatory actions play an important role in the cancer epithelial-mesenchymal transition (EMT). Mechanistically, we demonstrated that the overexpression of miR-183 decreased the expression of PDCD4 (programmed cell death 4) mRNA and protein, and vice versa. This helped to identify PDCD4 as the target genes in pancreatic cancer. In conclusion, our analyses indicated miR-183 to be an important contributor to cell migration. This could also be used as a potential therapeutic target for pancreatic cancer treatment. Copyright © 2015 Elsevier Masson SAS. All rights reserved.
    Biomedecine [?] Pharmacotherapy 03/2015; 70. DOI:10.1016/j.biopha.2015.01.016 · 2.11 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: In our previous study, miRNA-183, a miRNA in the miR-96-182-183 cluster, was significantly over-expressed in esophageal squamous cell carcinoma (ESCC). In the present study, we explored the oncogenic roles of miR-183 in ESCC by gain and loss of function analysis in an esophageal cancer cell line (EC9706). Genome-wide mRNA microarray was applied to determine the genes that were regulated directly or indirectly by miR-183. 3'UTR luciferase reporter assay, RT-PCR, and Western blot were conducted to verify the target gene of miR-183. Cell culture results showed that miR-183 inhibited apoptosis (p < 0.05), enhanced cell proliferation (p < 0.05), and accelerated G1/S transition (p < 0.05). Moreover, the inhibitory effect of miR-183 on apoptosis was rescued when miR-183 was suppressed via miR-183 inhibitor (p < 0.05). Western blot analysis showed that the expression of programmed cell death 4 (PDCD4), which was predicted as the target gene of miR-183 by microarray profiling and bioinformatics predictions, decreased when miR-183 was over-expressed. The 3'UTR luciferase reporter assay confirmed that miR-183 directly regulated PDCD4 by binding to sequences in the 3'UTR of PDCD4. Pearson correlation analysis further confirmed the significant negative correlation between miR-183 and PDCD4 in both cell lines and in ESCC patients. Our data suggest that miR-183 might play an oncogenic role in ESCC by regulating PDCD4 expression.
    Molecules and Cells 12/2014; DOI:10.14348/molcells.2014.0147 · 2.24 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Factors affecting serum prostate-specific antigen (PSA) levels in men are clinically important, but apart from effects mediated through the androgen receptor, they are poorly understood. To investigate whether microRNA (miRNA) affects the synthesis and serum levels of PSA. Reporter assays with PSA and KLK2 3' untranslated regions (UTRs) to confirm posttranscriptional regulation was followed by high-throughput screening of the effect of 1129 miRNAs on PSA levels using reverse phase protein arrays (RPPAs) to identify individual regulatory miRNAs. The candidate miRNAs were investigated further in vitro by Western blot, immunofluorometrics, activity assays, quantitative reverse transcriptase polymerase chain reaction, reporter assays, and growth assays. Prostate levels of miR-183 were compared with PSA transcript and serum PSA levels in prostate cancer cohorts. RankProd was used to evaluate the RPPAs, and the Student t test was used for the in vitro experiments. The Spearman and Cuzick tests were used in the patient material, and overall survival was analysed by Kaplan-Meier and log-rank analysis. Gain-of-function screenings identified 32 miRNAs that increase PSA levels. One of these, miR-183, was found to bind the 3' UTR of PSA directly and increase both protein and messenger RNA levels. Prostatic levels of miR-183 and serum PSA showed correlation in a cohort of 74 men. In addition, miR-183 promotes cellular growth in vitro and correlates to clinical parameters such as World Health Organisation grade and clinical progression. The synthesis and serum levels of PSA are directly affected by miR-183 and may be a factor to consider when PSA values are evaluated in clinical settings. These findings offer novel insights into the regulation of prostate-specific antigen and may eventually affect clinical decision making in prostate cancer. Copyright © 2014 European Association of Urology. Published by Elsevier B.V. All rights reserved.
    European Urology 12/2014; DOI:10.1016/j.eururo.2014.12.025 · 12.48 Impact Factor

Preview (2 Sources)

Download
3 Downloads
Available from